Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells

Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20–40% of patients to generate anti-tumor immune responses. Combination treatment approaches with chemotherapeutic drugs may enable responses in the remaining patient cohorts. In this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauzon, Maxine, Drake, Penelope M., Barfield, Robyn M., Cornali, Brandon M., Rupniewski, Igor, Rabuka, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422391/
https://www.ncbi.nlm.nih.gov/pubmed/30906660
http://dx.doi.org/10.1080/2162402X.2019.1565859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422391/
https://www.ncbi.nlm.nih.gov/pubmed/30906660
http://dx.doi.org/10.1080/2162402X.2019.1565859

Ejemplares similares